共 50 条
- [41] OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Pistilli, BarbaraBellet, MeritxellDel Mastro, LuciaMcArthur, Heather L.Meisel, Jane LoweSchmid, PeterSohn, JoohyukDe Kermadec, ElisabethWei, RachelChan, Arlene
- [42] Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trialEBIOMEDICINE, 2022, 86Chandiwana, NomathembaKruger, ChelseaJohnstone, HilaryChughlay, Mohamed FaroukJu, ChungKim, ByungsuDineka, YengiweArbe-Barnes, SarahMiller, RobertOwen, AndrewHill, AndrewWindgassen, DanielAbla, NadaMarrast, Anne ClaireDuparc, StephanVenter, Willem Daniel Francois
- [43] Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyLANCET ONCOLOGY, 2012, 13 (02): : 181 - 188Lee, JeeyunPark, Se HoonChang, Heung-MoonKim, Jun SukChoi, Hye JinLee, Myung AhJang, Joung SoonJeung, Hei CheulKang, Jung HunLee, Hyun WooShin, Dong BokKang, Hye JinSun, Jong-MuPark, Joon OhPark, Young SukKang, Won KiLim, Ho Yeong
- [44] Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1) : a multicentre, open-label, randomised, controlled, phase 3 studyLANCET ONCOLOGY, 2024, 25 (10): : 1337 - 1346Dawson, Laura A.Ringash, JolieFairchild, AlysaStos, PaulDennis, KristopherMahmud, AamerStuckless, Teri LynnVincent, FrancoisRoberge, DavidFollwell, MatthewWong, Raimond K. W.Jonker, Derek J.Knox, Jennifer J.Zimmermann, CamillaWong, PhilipBarry, Aisling S.Gaudet, MarcWong, Rebecca K. S.Purdie, Thomas G.Tu, DongshengO'Callaghan, Christopher J.
- [45] Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 studyGYNECOLOGIC ONCOLOGY, 2023, 169 : 64 - 69Rubinstein, Maria M.Doria, Eric RiosKonner, JasonLichtman, StuartZhou, QinIasonos, AlexiaSarasohn, DebraTroso-Sandoval, TiffanyFriedman, ClaireO'Cearbhaill, RoisinCadoo, KarenKyi, ChrisannCohen, SethSoldan, KrystenBillinson, EricCaird, ImogenJang, DasomEid, KhalilShah, PoojaGuillen, JoyceAghajanian, CarolZamarin, DmitriyMakker, Vicky
- [46] Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancerANNALS OF ONCOLOGY, 2018, 29 (04) : 881 - 887Cortes, J.Perez-Garcia, J.Levy, C.Gomez Pardo, P.Bourgeois, H.Spazzapan, S.Martinez-Janez, N.Chao, T. -C.Espie, M.Nabholtz, J. M.Gonzalez Farre, X.Beliakouski, V.Roman Garcia, J.Holgado, E.Campone, M.
- [47] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 studyLANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041Hurvitz, Sara A.Bardia, AdityaQuiroga, VanesaPark, Yeon HeeBlancas, IsabelAlonso-Romero, Jose LuisVasiliev, AleksandrAdamchuk, HryhoriySalgado, MarceloYardley, Denise A.Berzoy, OleksandrZamora-Aunon, PilarChan, DavidSpera, GonzaloXue, ClorisFerreira, ErikaCrnjevic, Tanja BadovinacPerez-Moreno, Pablo DiegoLopez-Valverde, VanesaSteinseifer, JuttaFernando, Tharu M.Moore, Heather M.
- [48] Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trialLANCET HAEMATOLOGY, 2017, 4 (12): : E573 - E583Aguilar-Guisado, ManuelaEspigado, IldefonsoMartin-Pena, AlmudenaGudiol, CarlotaRoyo-Cebrecos, CristinaFalantes, JoseVazquez-Lopez, LourdesIsabel Montero, MariaRosso-Fernandez, Clarade la Luz Martino, MariaParody, RocioGonzalez-Campos, JoseGarzon-Lopez, SebastianCalderon-Cabrera, CristinaBarba, PereRodriguez, NancyRovira, MontserratMontero-Mateos, EnriqueCarratala, JordiAntonio Perez-Simon, JoseMiguel Cisneros, Jose
- [49] Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyLANCET ONCOLOGY, 2019, 20 (08): : 1070 - 1082Bekaii-Saab, Tanios S.Ou, Fang-ShuAhn, Daniel H.Boland, Patrick M.Ciombor, Kristen K.Heying, Erica N.Dockter, Travis J.Jacobs, Nisha L.Pasche, Boris C.Cleary, James M.Meyers, Jeffrey P.Desnoyers, Rodwige J.McCune, JeanninesPedersen, KatrinaBarzi, AfsanehChiorean, E. GabrielaSloan, JeffreyLacouture, Mario E.Lenz, Heinz-JosefGrothey, Axel
- [50] Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Okines, Alicia Frances ClareBraybrooke, JeremyMacPherson, Iain R.Sutherland, StephanieHowell, Sacha JonWheatley, DuncanWaters, SimonRoylance, RebeccaBaird, Richard D.Oikonomidou, OlgaPalmieri, CarloHarries, MarkHarper-Wynne, CatherineSheri, AmnaKhan, SarahBunce, CateyMohammed, KabirLee, DymphnaTurner, Nicholas C.